Topic summary

Revisiting: Oral versus injected administration claims for BPC-157

Compounds › Repair & healing peptides observational data needs a source TB-500 BPC-157 preprint Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 28, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

i.guerreroTL226 Feb 2025#1

On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion.

A follow-up question about Oral versus injected administration claims that I did not know to ask the first time.

The earlier thread answered what I asked. What I should have asked is below, and I think it is the one that matters.

55 likes 17mo

r.ilungaTL2 Solution10 Mar 2025#4

I had written a reply contradicting the opening post and deleted it. Here is what survived.

What I would check first on Oral versus injected administration claims is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.

10 likes 17mo

s.karlsen_rphTL3Pharmacist26 Mar 2025#10

Worth separating two things that post #8 runs together.

Whatever the answer on Oral versus injected administration claims turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.

31 likes 16mo

a.cabreraTL218 Apr 2025#20

This follows post #19 rather than contradicting it.

I would keep Oral versus injected administration claims and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.

32 likes 15mo

f.wojcikTL226 Apr 2025#24

Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.

30 likes 15mo

Read the full topic (28 posts)

This topic was referenced in

Why plausible mechanism is not evidence of effectCompounds › Repair & healing peptides · 18 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Publication patterns in the BPC-157 literature, examined Compounds › Repair & healing peptides preprint BPC-157 TB-500 needs a source Solved Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. Putting the numbers in the first post, because a question about…	+40	45	3.4k	21h
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Compounds › Repair & healing peptides TB-500 preprint observational data needs a source Solved On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. The question about BPC-157 that I actually want…	+77	84	54k	11mo
Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides BPC-157 observational data preprint TB-500 Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin oral versus injected administration claims…	+20	24	47k	4mo
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Compounds › Repair & healing peptides observational data TB-500 BPC-157 preprint Solved Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about…	+50	55	7.8k	2d
Why plausible mechanism is not evidence of effect — one year on Compounds › Repair & healing peptides needs a source preprint BPC-157 Solved Closed The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. What changes if the standard account of plausible…	+3	7	3.6k	13mo

Related topics — sharing the tags observational data, needs a source, TB-500

Topic	Participants	Replies	Views	Activity
About the Study critique category Evidence › Study critique risk of bias confounding observational data Pinned Wiki Structured criticism of a specific published study. Criticise the method, not the author. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…		4	114	16mo
Stability of BPC-157 in solution: what has been measured Compounds › Repair & healing peptides BPC-157 observational data needs a source TB-500 Stability of BPC-157 in solution: what has been measured — setting out what I have, and where I think it stops being reliable. Something about stability of BPC-157 does not reconcile and I would like a second…		2	805	30d
Naming conventions for research peptides and the confusion they cause — one year on Compounds › Other compounds research use only mislabelling needs a source Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. Asking about Naming conventions for research peptides…	+1	5	181	2y
BPC-157: what the rodent literature actually shows, and what it does not Compounds › Repair & healing peptides observational data preprint BPC-157 needs a source BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I would like to know what people here actually do about BPC-157,…	+44	48	3k	10mo
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide randomised trial preprint effect size retatrutide Solved Closed On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. Asking about retatrutide phase 2 in type on behalf of the question I keep seeing…	+12	16	50k	12mo